Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives "Buy" Rating from HC Wainwright

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $70.00 target price on the stock. HC Wainwright's target price points to a potential upside of 34.51% from the company's current price.

RYTM has been the topic of several other research reports. Stifel Nicolaus assumed coverage on Rhythm Pharmaceuticals in a research report on Wednesday, March 5th. They set a "buy" rating and a $78.00 price target on the stock. Jefferies Financial Group started coverage on shares of Rhythm Pharmaceuticals in a research report on Thursday, January 2nd. They set a "buy" rating and a $80.00 price target on the stock. Oppenheimer assumed coverage on shares of Rhythm Pharmaceuticals in a research report on Friday, December 20th. They issued an "outperform" rating and a $76.00 price objective for the company. Canaccord Genuity Group boosted their price objective on shares of Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Finally, The Goldman Sachs Group raised their target price on shares of Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the company a "buy" rating in a research note on Thursday, December 5th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Rhythm Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $69.46.

Remove Ads

Rhythm Pharmaceuticals Trading Down 4.0 %

Shares of RYTM opened at $52.04 on Monday. The stock has a market capitalization of $3.29 billion, a price-to-earnings ratio of -12.02 and a beta of 2.30. Rhythm Pharmaceuticals has a 12 month low of $35.17 and a 12 month high of $68.58. The firm has a fifty day simple moving average of $55.30 and a 200 day simple moving average of $54.96.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). The business had revenue of $41.83 million for the quarter, compared to analyst estimates of $38.48 million. Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. As a group, research analysts predict that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Rhythm Pharmaceuticals news, CAO Christopher Paul German sold 635 shares of Rhythm Pharmaceuticals stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total value of $36,334.70. Following the completion of the sale, the chief accounting officer now owns 2,070 shares in the company, valued at $118,445.40. The trade was a 23.48 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Yann Mazabraud sold 75,000 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the transaction, the executive vice president now owns 40,370 shares in the company, valued at approximately $2,078,247.60. The trade was a 65.01 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 107,787 shares of company stock valued at $5,762,443. Insiders own 5.60% of the company's stock.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Castleark Management LLC raised its holdings in Rhythm Pharmaceuticals by 1.3% in the 3rd quarter. Castleark Management LLC now owns 19,260 shares of the company's stock valued at $1,009,000 after acquiring an additional 250 shares in the last quarter. Two Sigma Advisers LP increased its position in shares of Rhythm Pharmaceuticals by 2.3% in the fourth quarter. Two Sigma Advisers LP now owns 13,100 shares of the company's stock worth $733,000 after purchasing an additional 300 shares during the period. SRS Capital Advisors Inc. lifted its position in Rhythm Pharmaceuticals by 740.7% during the fourth quarter. SRS Capital Advisors Inc. now owns 454 shares of the company's stock worth $25,000 after purchasing an additional 400 shares during the period. Raleigh Capital Management Inc. acquired a new stake in Rhythm Pharmaceuticals during the fourth quarter worth about $28,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Rhythm Pharmaceuticals by 2.0% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,156 shares of the company's stock valued at $1,857,000 after buying an additional 654 shares during the period.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.